Search details
1.
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
N Engl J Med
; 390(10): 875-888, 2024 Mar 07.
Article
in English
| MEDLINE | ID: mdl-38446675
2.
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.
Nature
; 595(7867): 432-437, 2021 07.
Article
in English
| MEDLINE | ID: mdl-34135506
3.
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1).
Br J Cancer
; 130(3): 434-441, 2024 02.
Article
in English
| MEDLINE | ID: mdl-38102226
4.
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
N Engl J Med
; 384(12): 1125-1135, 2021 03 25.
Article
in English
| MEDLINE | ID: mdl-33577729
5.
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide.
Prostate
; 83(4): 376-384, 2023 Mar.
Article
in English
| MEDLINE | ID: mdl-36564933
6.
Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma.
Oncologist
; 28(1): 59-71, 2023 01 18.
Article
in English
| MEDLINE | ID: mdl-35881028
7.
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study.
Invest New Drugs
; 41(5): 677-687, 2023 10.
Article
in English
| MEDLINE | ID: mdl-37556023
8.
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study.
BMC Cancer
; 23(1): 1056, 2023 Nov 03.
Article
in English
| MEDLINE | ID: mdl-37919668
9.
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 23(3): 393-405, 2022 03.
Article
in English
| MEDLINE | ID: mdl-35157830
10.
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.
Cancer
; 128(11): 2085-2097, 2022 06 01.
Article
in English
| MEDLINE | ID: mdl-35383908
11.
Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy.
Oncologist
; 27(12): 1048-1057, 2022 12 09.
Article
in English
| MEDLINE | ID: mdl-36146944
12.
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
N Engl J Med
; 381(26): 2506-2518, 2019 12 26.
Article
in English
| MEDLINE | ID: mdl-31566937
13.
Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer.
BJU Int
; 130(5): 592-603, 2022 11.
Article
in English
| MEDLINE | ID: mdl-34597472
14.
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.
Br J Clin Pharmacol
; 88(7): 3182-3192, 2022 07.
Article
in English
| MEDLINE | ID: mdl-35029306
15.
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(4): 525-537, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33721560
16.
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Lancet
; 395(10241): 1907-1918, 2020 06 20.
Article
in English
| MEDLINE | ID: mdl-32473681
17.
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
N Engl J Med
; 378(14): 1277-1290, 2018 Apr 05.
Article
in English
| MEDLINE | ID: mdl-29562145
18.
Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice.
J Urol
; 206(2): 240-251, 2021 08.
Article
in English
| MEDLINE | ID: mdl-33835866
19.
Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma.
J Urol
; 205(2): 414-419, 2021 02.
Article
in English
| MEDLINE | ID: mdl-32935617
20.
Outcomes of systemic targeted therapy in recurrent renal cell carcinoma treated with adjuvant sunitinib.
BJU Int
; 128(2): 254-261, 2021 08.
Article
in English
| MEDLINE | ID: mdl-33547860